Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

LEUVEN, Belgium, November 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the nine months period ended 30 September 2008.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs continue to progress as anticipated. We are now working hard to prepare for the Phase III clinical program for microplasmin in eye disease following a successful End of Phase II Meeting with the FDA. The recent positive results from our Phase II trials with microplasmin have given us further confidence that this product has the potential to make a real difference in the field of eye disease. We are also developing a good working relationship with our strategic partner Roche as the clinical development of our new anti-cancer antibody TB-403 continues to progress. With our solid financial situation, I believe that ThromboGenics will deliver further important corporate milestones over the next 12 to 18 months as we continue to work to build value for our shareholders."
Financial Update

- In the first nine months of 2008, ThromboGenics achieved

revenues of EUR 30.3 million, mainly from out-licensing activities.

Operating expenses were EUR 17.0 million during this nine month period,

the majority of which were due to R&D expenses related to an increasing

number of clinical development programs.

- As of 30 September 2008, ThromboGenics had EUR 60.9 million

in cash and cash equivalents. This compares to EUR 50.6 million on 30

September 2007 and EUR 40.1 million on 31 December 2007. ThromboGenics

believes that this level of funding will allow it to complete the Phase

III program for the initial indication for microplasmin in eye disease.

- In late July, ThromboG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... even the entire body to visualize long-range connections between ... a long-time dream of biologists. A study published by ... Cell has now made that dream a ... and human tissue biopsies transparent, while keeping the cellular ... way for a better understanding of brain-body interactions, more ...
(Date:7/31/2014)... July 31, 2014 Rogne Bioscience, a privately-held ... Area , has acquired a licence to anti-inflammatory ... company. The potent anti-inflammatory activity of the peptides was ... University of Oxford,s Sir William Dunn School ... raised over $1.5 million in seed financing, is developing ...
(Date:7/31/2014)... 2014 CollabRx, Inc. (NASDAQ: CLRX), a ... in oncology, today announced that it will hold an ... the Company's financial results for the first quarter of ... business in the current fiscal year. , The dial-in ... August 14, 2014, at 5 p.m. EDT (2 p.m. ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... today the integration of Omicsoft’s Array Suite with ... platforms will be able to send data in tranSMART ... works with all versions of tranSMART including the new ... art statistics, visualization and storage for the analysis of ...
Breaking Biology Technology:See-through organs and bodies will accelerate biomedical discoveries 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3
... May 25, 2011 Otonomy, Inc., ... for diseases and disorders of the inner and ... Wroblewski as the company,s chief operations officer.  Mr. ... the areas of manufacturing, product supply chain management, ...
... Lund, Sweden, researchers can study a wide range of different ... This could be useful for both basic research and industry ... DanishSwedish collaboration. Now it is opening for research. The ... is used to examine the components of materials and their ...
... Spherix Incorporated (NASDAQ: SPEXD) – an ... syndrome and atherosclerosis, and providers of technical and ... pharmaceutical companies – today announced that it has ... concerns minimum bid price listing requirements. ...
Cached Biology Technology:Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 2Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 3New beamline at MAX II opens for research 2Spherix Regains Compliance With NASDAQ Listing Rule 2
(Date:7/31/2014)... available in German . ... gases similar to a sponge that soaks up liquids. ... hydrogen or greenhouse gases. However, loading of many MOFs ... Technology (KIT) now report in Nature Communications ... MOF surface. This can be prevented by water-free synthesis ...
(Date:7/31/2014)... better identify and treat those with fibromuscular dysplasia (FMD). ... sized arteries in the body, which can restrict blood flow ... new report appearing in August 2014 issue of ... FMD may not be limited to the arteries as currently ... bones and joints, as well as evidence that inflammation may ...
(Date:7/31/2014)... found that bacteria in the Gulf of Mexico consumed ... during the Deepwater Horizon spill in the months after ... In two new studies conducted in a deep sea ... bacteria called Colwellia likely consumed gaseous hydrocarbons ... were released as part of the oil spill. ...
Breaking Biology News(10 mins):Free pores for molecule transport 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... in soils are as diverse in the tropical forests of Costa ... the tundra and boreal forests of Alaska and Sweden. That ... Proceedings of the National Academy of Sciences . Scientists ... found above ground at the equator than at the Earth,s poles. ...
... series are already enjoying the advantages of synthetic blood. While ... big screen, the true benefits of blood manufactured from embryonic ... It is unclear however whether society can develop an acceptance ... produced by related technology. For this reason it is ...
... WASHINGTON and LONDON On the heels of a ... D.C., leaders of the U.S. National Academy of Sciences and ... global insurance and reinsurance broker headquartered in the U.K., pledged ... financial resilience of populations to extreme events. Although 2011 ...
Cached Biology News:From tropics to poles: Study reveals diversity of life in soils 2Can we share vampires' appetite for synthetic blood? 2US science academy and global reinsurance broker spark 2US science academy and global reinsurance broker spark 3US science academy and global reinsurance broker spark 4
...
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
... Experion software, PC, is used ... the data obtained from the Experion ... data in electropherogram and simulated gel ... other calculations in a Results table. ...
Biology Products: